Core Viewpoint - Apollo Biowellness, Inc. has received approval to file on OTCIQ and is actively pursuing multiple strategic initiatives to enhance its product offerings and market presence [1][6]. Group 1: Product Development - The company is in final negotiations with a NASDAQ-listed Israeli Bio-Tech manufacturer for the co-development of a shelf-stable biologic cosmetic named Ceilo Skin Care, set to launch in Q4 2025 [3]. - Apollo plans to introduce a unique Pet and Veterinarian Biologic product utilizing exosomes and placental products, targeting issues like arthritis and inflammation in pets, with a launch before the end of Q3 2025 [5]. Group 2: Strategic Partnerships - The company is negotiating with a large aesthetic company specializing in Laser Energy Devices for a potential merger or business combination to create a combined therapy company [4]. Group 3: Financial Strategy - Apollo is working with its debt holders and convertible note holders to restructure, refinance, or convert most positions to a preferred class of equity, aligning with management's growth financing plans for the next 12 months [6]. Group 4: Company Overview - Apollo Biowellness, Inc. and its subsidiary, Evolutionary Biologics, Inc., focus on discovering, developing, and marketing biologic-based products aimed at improving human health, positioning itself as a leader in Regenerative Medicine [7][8].